Sabra Health Care REIT Stock Price and Value Analysis

Sabra Health Care REIT (NasdaqGS:SBRA) with its current price, filing history and research links below. Our cash flow valuation does not fit this type of company, so there is no fair price.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Inside the SBRA Numbers

SBRA Price
(Sabra Health Care REIT stock price per share)
$20.39
[?] PE Ratio versus Sector 469% higher than other Financial Services stocks
[?] PE Ratio versus Industry 21% higher than other REIT - Diversified stocks
[?] Dividend Yield 5.87% (tax impact)
Shares Shorted 17,882,953

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 17,882,953 shares shorted. With 257,599,803 shares available for purchase and an average trading volume over the past 10 trading days of 2,519,960, it would take at least 7.1 days for all of the short holders to cover their shorts.

Why This Page Shows No Fair Price

Trendshare's cash flow valuation is built for operating companies, which sell goods or services and keep what is left after paying for the equipment they need. It does not fit banks, insurers, real estate investment trusts (REITs) or funds. Their cash flows include deposits, loan repayments, insurance premiums and distributions the company must pay out, so free cash flow does not measure what the business earns for its owners. For that reason this page shows no fair price, safety price or price comparison for Sabra Health Care REIT. The price and basic facts above come from market data, and the filing history below comes from the company's own SEC reports.

To judge a company like this, read its filings on SEC EDGAR. Our investment guide explains the measures that suit each kind of company.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 469% above the average for stocks in the Financial Services sector.

Its trailing P/E ratio is 21% above the average for stocks in the REIT - Diversified industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the REIT - Diversified industry, the ones closest in market capitalization to Sabra Health Care REIT, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yield
Sabra Health Care REIT (SBRA) 5,341 75.5 5.9%
Outfront Media (OUT) 5,491 21.2 3.9%
Kite Realty Group Trust (KRG) 5,003 15.3 4.7%
Cousins Properties Incorporated (CUZ) 4,726 319.0 4.4%
Rayonier (RYN) 6,017 32.7 5.2%
Tanger Factory Outlet Centers (SKT) 4,557 34.7 3.2%
Apple Hospitality REIT (APLE) 4,486 24.1 5.0%

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $84.2 million in 2011 and $775 million in 2025, a compound annual growth rate of 17.2% over 14 years.

Revenue rose 10.2% from 2024 to 2025.

Our estimated free cash flow was $349 million in 2025, 45.0% of revenue. In 2011 the estimated margin was 53.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2011 84.2 44.7 53.1%
2012 103 56.3 54.5%
2013 135 62.1 46.1%
2014 184 85.3 46.5%
2015 239 121 50.7%
2016 261 176 67.5%
2017 408 136 33.3%
2018 623 361 57.8%
2019 662 372 56.3%
2020 599 355 59.3%
2021 570 356 62.6%
2022 625 316 50.5%
2023 648 301 46.4%
2024 703 311 44.2%
2025 775 349 45.0%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $71.5 million against total liabilities of $2,670 million, or 2.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 48.6% of total assets in 2025, compared with 70.2% in 2010, a decrease of 21.6 percentage points.

Stockholders equity was $2,824 million in 2025, compared with $178 million in 2010, a rise of 1490.6%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 6.4% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 596 42.2 418 178
2011 750 42.2 423 327
2012 917 17.1 611 305
2013 1,174 4.3 713 460
2014 2,065 61.8 1,123 942
2015 2,469 7.4 1,415 1,054
2016 2,266 25.7 1,250 1,016
2017 7,032 519 3,595 3,437
2018 6,665 50.2 3,411 3,255
2019 6,069 39.1 2,581 3,488
2020 5,986 59.1 2,576 3,409
2021 5,967 112 2,587 3,380
2022 5,748 49.3 2,691 3,056
2023 5,386 41.3 2,584 2,803
2024 5,304 60.5 2,562 2,741
2025 5,493 71.5 2,670 2,824

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1492298.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

This analysis covers US companies that file 10-K annual reports. No fair price is shown for this company, because free cash flow does not describe banks, insurers, real estate investment trusts and funds. In the balance sheet and revenue tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: SBRA annual reports (10-K) on SEC EDGAR. Our editorial standards explain how Trendshare handles its sources and corrections.

Questions to Answer Before You Invest in SBRA

Does Sabra Health Care REIT have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.